Publications by authors named "Sumie Koike"

Claim this Profile
O
Osteocyte-like differentiation of osteosarcoma by inorganic phosphate.
Yuya Suzuki, Makoto Takeuchi, Sumie Koike, Satoshi Takagi, Ryohei Katayama

Differentiation· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of anti-apoptotic Bcl-2 family members promotes synergistic cell death with ER stress inducers by disrupting autophagy in glioblastoma.
Tianyi Huang, Satoshi Takagi, Sumie Koike, Ryohei Katayama

Cell Death Discov· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma.
Satoshi Takagi, Mikako Nakajima, Sumie Koike, Miho Takami, Yoshiya Sugiura

Oncogene· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
Xinzhao Wei, Ken Uchibori, Nobuyuki Kondo, Takahiro Utsumi, Ai Takemoto, Sumie Koike

Cancer Lett· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Takuya Sakashita, Noriko Yanagitani, Sumie Koike, Siew-Kee Low, Satoshi Takagi

Cancer Sci· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.
Yuki Shimizu, Koutaroh Okada, Jun Adachi, Yuichi Abe, Ryohei Narumi, Sumie Koike

NPJ Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis.
Satoshi Takagi, Yuki Sasaki, Sumie Koike, Ai Takemoto, Yosuke Seto

Oncogene· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.
Takahiro Yoshizawa, Ken Uchibori, Mitsugu Araki, Shigeyuki Matsumoto, Biao Ma, Sumie Koike

NPJ Precis Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Noriko Yanagitani, Ken Uchibori, Sumie Koike, Mika Tsukahara, Satoru Kitazono

Cancer Sci· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Sumie Koike

Nat Commun· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, Biao Ma, Ryo Kanada, Sumie Koike

EBioMedicine· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.
Kana Sakamoto, Ryohei Katayama, Reimi Asaka, Seiji Sakata, Satoko Baba, Sumie Koike

Leukemia· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Ryohei Katayama, Takuya Sakashita, Noriko Yanagitani, Hironori Ninomiya, Atsushi Horiike, Sumie Koike

EBioMedicine· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L Lockerman, Sumie Koike

Clin Cancer Res· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L Lockerman, Tahsin M Khan

Clin Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2.
Satoshi Takagi, Shigeo Sato, Tomoko Oh-hara, Miho Takami, Sumie Koike

PLoS One· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies.
Youya Nakazawa, Satoshi Takagi, Shigeo Sato, Tomoko Oh-hara, Sumie Koike

Cancer Sci· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells.
Aya Misawa, Ryohei Katayama, Sumie Koike, Akihiro Tomida, Toshiki Watanabe

Oncol Res· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
Ryohei Katayama, Sumie Koike, Shigeo Sato, Yoshikazu Sugimoto, Takashi Tsuruo

Cancer Sci· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.
Hiroshi Tanaka, Yutaka Hoshikawa, Tomoko Oh-hara, Sumie Koike, Mikihiko Naito

Mol Cancer Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis